Figure 6.

A. Intraoperative images of a partially resected brain tumor comparing images obtained by conventional bright-field, or white light, imaging (left) versus PS (mTHPC) fluorescence imaging under blue light (A, right) The partially resected brain tumor is difficult to discern, while it is readily apparent in the PS fluorescence image of the same tissue. Image adapted from Zimmermann et al (2001).⁶² B. Ex vivo tissue whole mount immunofluorescence image of a microscopic metastasis (micrometastasis) from a mouse model of peritoneal carcinomatosis where an EGFR-targeted, activatable PS-antibody conjugate (immunoconjugate) has been taken up and activated by tumor cells in vivo (red). An anti-mouse CD31 antibody has been applied to label endothelial cells (green). This development is further explained in Figure 7 and enables tumor recognition and PDT with microscale selectivity. Image is adapted from Spring (2014) et al.⁴